- Valneva SE has signed a new $32.8 million contract with the U.S. Department of Defense (DoD) for the supply of its Japanese encephalitis vaccine, IXIARO.
- The one-year contract continues the relationship with the DoD, with the possibility for additional purchases in the coming year.
Valneva SE, a specialty vaccine company, has secured a new one-year contract worth $32.8 million with the U.S. Department of Defense (DoD). Under this agreement, the DoD will purchase IXIARO, a vaccine for Japanese encephalitis (JE), with the possibility of additional orders over the next twelve months.
The contract is an extension of the supply agreement that began in September 2023. Deliveries for 2024 have already been underway, and this new contract will commence immediately.
“We are honored to continue our long-term relationship with the DoD,” said Dipal Patel, Chief Commercial Officer of Valneva. “The U.S. military has trusted IXIARO for over ten years to help protect military personnel, their families, civilian government service personnel, and government contractors from this potentially deadly disease.”
IXIARO is the only Japanese encephalitis vaccine approved by the U.S. Food and Drug Administration (FDA). The vaccine was developed through a cooperative research and development agreement with the Walter Reed Army Institute of Research and is marketed directly to the U.S. military and the private travel market by Valneva.